Bryan Kohberger’s Unsealed Psych Evaluation Lists Eight Diagnoses: Autism, OCD, ADHD, an Eating Disorder, Coordination Disorder, Depression, Anorexia and a Heroin Addiction Now in Remission
Kohberger first told the court about four diagnoses. The unsealed evaluation adds four more he never listed, including a teenage heroin addiction now in remission.
The full neuropsychological evaluation behind Bryan Kohberger’s diagnoses was sealed until now, and it lists twice as many conditions as he ever disclosed. Kohberger’s own 2025 court filing named four: autism (Level 1), OCD, ADHD and the eating disorder ARFID. The unsealed report from psychologist Rachel Lawson Orr adds four more he met the criteria for in the past: developmental coordination disorder, an unspecified depressive disorder, anorexia nervosa and opioid use disorder tied to a heroin addiction from his teenage years, which Orr noted is in sustained remission.

Orr, hired by Kohberger’s defense, met with him on six occasions over three months. She wrote that he showed a “restricted range of facial expression, with stoic effect at baseline,” inconsistent or absent social smiling, and atypical social behaviors that included occasional intense gaze and repeatedly steering conversation back to himself. His parents and two sisters, interviewed as part of the process, described “rigid thinking and behavior” and trouble coping with changes in routine, and said years of social coaching had gone “to no avail.”

The evaluation was never meant to support an insanity defense. Kohberger’s attorney Anne Taylor argued his mental health should count as a mitigating factor at sentencing, while prosecutors wanted it treated as an aggravator.

Kohberger confessed on July 2, 2025, to killing University of Idaho students Madison Mogen, 21; Kaylee Goncalves, 21; Xana Kernodle, 20; and Ethan Chapin, 20. He was sentenced to four life terms. In July 2026 he filed a motion to withdraw his guilty plea and get a trial, citing ineffective counsel.
Thanks for reading Thought Catalog. Join us on Facebook, or keep reading on our website.
